LATEST PSYCHEDELICS STOCKS NEWS

Calendar136 views3 min read

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit

Psyence Group
TORONTO, Nov. 26, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit, a gathering of i... Read More...
420 views2 min read

Numinus Announces Departure of Stacey Wallin

Numinus Wellness
VANCOUVER, BC, Nov. 25, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today following the conclusion of several weeks of discussions that Stacey Wallin, former Chief Strategy Officer, is no longer with t... Read More...
395 views8 min read

Allied Corp Signs Yearly Supply Contract With Veterans for Healing Using the Allied Inside™ Business Model With Colombian Produced Cannabis Flower

Allied
KELOWNA, British Columbia, Nov. 24, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the signing of a supply contract (the “contract”) for the 2022 calendar year and beyond. Allied will be only exporting cannabis flower after the Colombian government allows it and will provide supply only to countries ... Read More...
1260 views3 min read

Novamind Unveils New Logo and Invests in Unified Brand

Novamind
TORONTO, ON / ACCESSWIRE / November 24, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, today launched a new logo and announced that the Company will unite its subsidiaries and brands under a single Novamind brand.Novamind is investing in a revitalized ... Read More...
569 views4 min read

PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

PharmaTher Holdings
Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndromeStrengthens commitment to treat rare disorders and life-threatening conditions with ketamine TORONTO, Nov. 24, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-... Read More...
274 views4 min read

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics
TORONTO, Nov. 23, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administrat... Read More...
59 views1 min read

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

Silo Pharma
Englewood Cliffs NJ, Nov. 18, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal techno... Read More...
101 views3 min read

Pure Extracts Reaches Production Milestone of 2,200 lbs of Cannabis and 3,300 lbs of Hemp

Pure Extracts Technologies
VANCOUVER, British Columbia, Nov. 18, 2021 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pu... Read More...
66 views8 min read

Delic Launches Industry’s First Family Support & Education Program at Ketamine Wellness Centers (KWC) Nationwide For Patient Community

Delic Holdings
Nation's Largest Chain of Ketamine Wellness Clinics Introduces First-of-Its-Kind Virtual Programming to Help Patients' Loved Ones Prepare for Life After Ketamine Infusion Experience VANCOUVER, BC, Nov. 18, 2021 - Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatment... Read More...
41 views7 min read

Nutritional High International Inc. Announces Its Name Change to High Fusion Inc

Nutritional High International
Toronto, Ontario--(Newsfile Corp. - November 16, 2021) - Nutritional High International Inc. (CSE: FUZN) (OTCQB: SPLIF) (the "Company") is pleased to announce that following approval by the shareholders at the last annual and special meeting of shareholders held on September 29, 2021, it has completed its name change from "Nutritional Hig... Read More...
40 views8 min read

Allied Corp Progresses Towards Clinical Phase I Trial for Psilonex™ RX Psilocybin Pharma Drug

Allied
KELOWNA, British Columbia, Nov. 16, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the advancement of the Psilonex™ RX human clinical phase I trial. Allied has now sourced the active pharmaceutical ingredients contained in Psilonex™ and is now moving towards producing the Psilonex™ to be used at one ... Read More...
Financials138 views46 min read

Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update

Mydecine Innovations Group
--To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year Research Agreement with JHU to Further Mydecine’s Research of Multiple Molecules for a Variety of Indications -- DENVER, Nov. 16, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a ... Read More...
946 views4 min read

Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

Revive Therapeutics
TORONTO, Nov. 16, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a research study, titled “Thiol drugs decrease SARS-CoV-2 lung injury in ... Read More...
1095 views9 min read

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory

Red Light Holland
Red Light Holland is continuing its groundbreaking working synergies with Shaman Pharma Corp. and their cGMP laboratory partner, CCrest Laboratories Inc. who holds a Controlled Drugs and Substances License issued by Health Canada Red Light Holland previously completed two exports, under Health Canada psilocybin import permits, for commerc... Read More...
Financials110 views35 min read

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results and Provides Business Update

Field Trip Health
Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications.Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk profile compared to classic psychedelics (the “FT-200 Group... Read More...
Financials54 views8 min read

Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights

Cybin
- Company to host conference call at 4:30pm EST today –TORONTO, November 15, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today reported unaudited financial results for its second quarter ended September 30... Read More...
895 views7 min read

Nutritional High International Inc. Provides Update on Commencement of Trading

Nutritional High International
Toronto, Ontario--(Newsfile Corp. - November 12, 2021) - Nutritional High International Inc. (CSE: FUZN) (OTCQB: SPLIF) (the "Company") announced today that its common shares remain halted pending the filing of articles of amendment to give effect to its name change from "Nutritional High International Inc." to "High Fusion Inc." (the "Na... Read More...
312 views5 min read

Inaugural Meet Delic Experience Sells Out, Becomes World’s Largest Psychedelic and Wellness Event

Delic Holdings
"We're incredibly humbled and unbelievably inspired by the number of people who came out to Meet Delic and joined the conversation on the power of psychedelics to heal and to remove the stigmas surrounding them," said Jackee Stang, co-founder of Delic. "The world and our minds have evolved, and so should our medicines. We're already look... Read More...
CalendarFinancials109 views1 min read

Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

Cybin
TORONTO, November 09, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM" today announced that it will report financial results for its second quarter of fiscal 2021 ended September 30, 2021 on Monday, November 15,... Read More...
M & A325 views12 min read

Delic Completes Acquisition of Ketamine Wellness Centers (KWC), Becomes Largest Psychedelic Wellness Chain in United States

Delic Holdings
National Presence Across 10 States Provides Millions with Access to New Medicines and Treatments for a Variety of Health Conditions Twelve Operational Today, 15 Additional Clinics to Open within 18 Months Kevin Nicholson, CEO of KWC, Promoted to Chief Operating Officer for Delic Corp VANCOUVER, BC, Nov. 9, 2021 - Delic Holdings Corp. ("D... Read More...
125 views9 min read

Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health

Cybin
Comparative CYB003 pre-clinical data on the Company’s deuterated psilocybin analog may have wide-reaching implications for the treatment of Major Depressive Disorder ("MDD") and Alcohol Use Disorder ("AUD") with less patient variability, faster onset of action, shorter duration of effect and improved brain penetrationTORONTO, November 08,... Read More...
Financials113 views1 min read

COMPASS Pathways plc to announce third quarter 2021 financial results on 9 November 2021

COMPASS Pathways plc
London, U.K., Nov. 08, 2021 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2021, and provide an update on recent business developments, on 9 November 202... Read More...
120 views3 min read

Blackhawk Growth’s MindBio Therapeutics Completes Safety Milestone in its Phase 1 Clinical Trials

Blackhawk Growth
Calgary, Alberta --News Direct-- Blackhawk Growth Corp.Blackhawk Growth Corp.Vancouver, British Columbia - TheNewswire - November 08, 2021 - Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its wholly owned subsidiary, MindBio Therapeutics Pty Ltd (“MindBio”),... Read More...
Financials1353 views2 min read

Novamind Announces Cease Trade Order and Delay in Filing Annual Financial Statements

Novamind
TORONTO, ON / ACCESSWIRE / November 4, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, today announced that it is the subject of a failure-to-file cease trade order issued by the Ontario Securities Commission on November 3, 2021 as a result of the Compa... Read More...
1151 views3 min read

Pure Extracts Receives Re-Order from Abba Medix Medical Platform for Vapes and Edibles

Pure Extracts Technologies
VANCOUVER, British Columbia, Nov. 04, 2021 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pu... Read More...
595 views6 min read

MINDCURE Provides Update on Studies and Clinical Trials

Mind Cure Health
VANCOUVER, BC, Nov. 4, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelics, is pleased to provide an operational progress update on the strategic initiatives of its operating segments - MINDCURE Research and MINDCURE Technology. MINDCURE... Read More...
1281 views5 min read

Optimi Health Engages Expert Management Consultancy to Drive Corporate Visibility

Optimi Health
VANCOUVER, British Columbia, Nov. 03, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is pleased to announce the engagement of management... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!